Skip to main content

Table 1 Recent advances and challenges of bispecific antibodies in solid tumor

From: Recent advances and challenges of bispecific antibodies in solid tumors

Targets BsAb Status Phase NCT Number Conditions
EpCAM/CD3 Catumaxomab Completed II NCT01065246 Malignant Ascites Due to Epithelial Carcinoma
Completed II NCT00377429 Ovarian Cancer
Completed II NCT00464893 Gastric Cancer, Gastric Adenocarcinoma
Completed II NCT01246440 Ovarian Cancer
Completed II NCT01504256 Gastric Adenocarcinoma With Peritoneal Carcinomatosis
Completed II NCT00326885 Malignant Ascites
Completed II NCT01815528 Recurrent Epithelial Ovarian Cancer
Completed III NCT00822809 Cancer, Neoplasms
Completed II NCT00563836 Ovarian Cancer, Epithelial Ovarian Cancer
Completed II/III NCT00836654 EpCAM Positive Cancer
Completed II NCT00352833 Gastric Cancer, Gastric Adenocarcinoma
Completed II NCT00189345 Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Neoplasms
Not recruiting I/II NCT04799847 Bladder Cancer
Recruiting I NCT04819399 Urinary Bladder Neoplasms
Recruiting III NCT04222114 Stomach Neoplasms
Terminated I NCT01320020 Epithelial Cancer
Terminated II NCT01784900 Gastric Peritoneal Carcinomatosis
MT110 (AMG110) Completed I NCT00635596 Solid Tumors
CEA/CD3 MT111/AMG211/MEDI-565 Completed I NCT01284231 Gastrointestinal Adenocarcinomas
Terminated I NCT02291614 Gastrointestinal Cancer
RO6958688 (RG7802) Completed I NCT02650713 Solid Tumors
Completed I NCT02324257 Solid Tumors
Recruiting III NCT03337698 NSCLC
CEA/HSG TF2 (IMP288) Completed III NCT01221675 SCLC, CEA-expressing NSCLC
Withdrawn I NCT01273402 Metastatic Colorectal Cancer
Completed II NCT02587247 Metastatic Colorectal Cancer
Completed I NCT00860860 Colorectal Neoplasms
Unknown III NCT02300922 Metastatic Colorectal Cancer
PSMA/CD3 Pasotuxizumab (BAY 2010112, MT112, AMG 212) Completed I NCT01723475 Prostatic Neoplasms
Acapatamab (AMG160) Recruiting I NCT04822298 Non-Small Cell Lung Cancer
Recruiting I NCT03792841 Metastatic Castration-resistant Prostate Cancer
Recruiting III NCT04631601 Metastatic Castration-resistant Prostate Cancer
HPN424 Recruiting III NCT03577028 Advanced Prostate Cancer
MOR209/ES414 Completed I NCT02262910 Metastatic Castration-resistant Prostate Cancer
CC-1 Recruiting I NCT04104607 Metastatic Castration-resistant Prostate Cancer
Not yet recruiting III NCT04496674 Lung Cancer Squamous Cell
EGFR/MET Amivantamab (JNJ-61186372) Approved for marketing   NCT04599712 Metastatic NSCLC
Recruiting II NCT04945733 Stomach Neoplasms, Esophageal Neoplasm
Recruiting II NCT04965090 Metastatic NSCLC
Recruiting III NCT04538664 Metastatic NSCLC
Not recruiting III NCT04988295 NSCLC
Recruiting I NCT04606381 Advanced Solid Malignancies
Recruiting III NCT04487080 NSCLC
Recruiting I NCT02609776 NSCLC
Recruiting I NCT04077463 NSCLC
HER2/CD3 Ertumaxomab Terminated III NCT01569412 HER2/Neu Positive Advanced Solid Tumors
Terminated II NCT00351858 Metastatic Breast Cancer
Terminated II NCT00522457 Metastatic Breast Cancer
Terminated II NCT00452140 Metastatic Breast Cancer
HER2/HER3 MM111 Completed I NCT01097460 Breast Neoplasms
Completed I NCT00911898 HER2 Amplified Solid Tumors
Completed I NCT01304784 HER2 Amplified Solid Tumors
Terminated II NCT01774851 HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal Junction and Stomach
HER2/HER3 Zenocutuzumab (MCLA-128) Recruiting III NCT02912949 Solid Tumors Harboring NRG1 Fusion
GPC3/CD3 ERY974 Completed I NCT02748837 Solid Tumors
Recruiting I NCT05022927 Hepatocellular Carcinoma
PD1/PDL1 LY3434172 Completed I NCT03936959 Advanced Cancer
PDL1/TIM3 LY3415244 Terminated I NCT03752177 Advanced Cancer
PD-1/CTLA4 MEDI5752 Active I NCT03819465 Metastatic NSCLC
Recruiting I NCT03530397 Advanced Renal Cell Carcinoma
Recruiting I NCT04522323 Advanced Solid Tumors
DLL4/VEGF Navicixizumab (OMP-305B83) Not recruiting III NCT05043402 Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Completed I NCT02298387 Advanced Solid Tumor Malignancies
Completed I NCT03030287 Ovarian, Peritoneal or Fallopian Tube Cancer
Terminated I NCT03035253 Metastatic Colorectal Cancer
DLL4/VEGF ABL001 (NOV1501) Recruiting III NCT04492033 Advanced Solid Tumors
Completed I NCT03292783 Advanced Solid Tumors
CD3/GPA33 MGD007 Completed I NCT02248805 Colorectal Carcinoma
Active III NCT03531632 Metastatic Colorectal Cancer
CD64/EGFR MDX447 Completed I NCT00005813 Brain and Central Nervous System Tumors
  1. EpCAM epithelial cell adhesion molecule, CEA carcinoembryonic antigen, HSG human serum albumin, SCLC small cell lung cancer, NSCLC non-small cell lung cancer, PSMA prostate-specific membrane antigen, NRG1 neuregulin 1, GPC3 glypican 3, HCC hepatocellular carcinoma, PD-1 programmed cell death protein 1, PD-L1 programmed cell death ligand 1, TIM3 T cell immunoglobulin and mucin domain-containing protein 3, CTLA4 cytotoxic T lymphocyte associate protein-4, DLL4 delta-like ligand 4, VEGF vascular endothelial growth factor, EGFR epidermal growth factor receptor